AI assistant
ADVANCED MEDICAL SOLUTIONS GROUP PLC — Earnings Release 2018
Jul 5, 2018
7467_rns_2018-07-05_b8b65423-38bc-4a35-9124-361998614431.html
Earnings Release
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 6257T
Advanced Medical Solutions Grp PLC
05 July 2018
5 July 2018
Advanced Medical Solutions Group plc
("AMS" or the "Group")
Trading Update
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, today announces a trading update covering the six-month period 1 January to 30 June 2018.
AMS continues to make good progress across the Group and can confirm that trading is in line with the Board's expectations.
Chris Meredith, Chief Executive Officer of AMS, commented: "The Board is pleased with the ongoing performance of the business and we remain on track for the full year. We continue to be focused on our strategic objectives to grow organically and through acquisition whilst delivering innovation from our Research and Development pipeline."
The Group expects to publish its Interim Results for the period to 30 June 2018 on 12 September 2018.
For further information, please visit www.admedsol.com or contact:
| Advanced Medical Solutions Group plc | Tel: +44 (0) 1606 545508 |
| Chris Meredith, Chief Executive Officer Mary Tavener, Chief Financial Officer |
|
| Consilium Strategic Communications | Tel: +44 (0) 20 3709 5700 |
| Mary-Jane Elliott / Matthew Neal / Nicholas Brown | [email protected] |
| Investec Bank PLC (NOMAD & Broker) | Tel: +44 (0) 20 7597 5970 |
| Daniel Adams / Patrick Robb / Gary Clarence |
About Advanced Medical Solutions Group plc - see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands; ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.
AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 75 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 600 employees. For more information, please see www.admedsol.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
TSTLLFISDSISIIT